Literature DB >> 2180046

Gastrinoma.

C M Townsend1, J C Thompson.   

Abstract

The Zollinger-Ellison syndrome with its main symptom of massive gastric hypersecretion presents problems with both the medical and surgical approaches to treatment. Successful medical treatment depends on a life-long commitment to rigid medication schedules requiring careful ongoing supervision and is subject to pitfalls of compliance, drug side effects, drug resistance, and complications of persistent tumor growth. Surgical therapy carries risks of operative mortality and complications. If a low operative mortality can be maintained and the nutritional results after total gastrectomy are good, then it is the authors' opinion that the permanent relief from dangers of hypersecretion afforded by total gastrectomy makes surgery a worthwhile approach. Based on our operative experience in 34 patients and interpretation of the experience of others, we believe that resection of all tumor that can be resected, combined with total gastrectomy, is safe and dependable. The results compare well with those of long-term medical management.

Entities:  

Mesh:

Year:  1990        PMID: 2180046     DOI: 10.1002/ssu.2980060207

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  4 in total

1.  The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.

Authors:  Federica Cioppi; Luisella Cianferotti; Laura Masi; Francesca Giusti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

2.  Mechanisms of bombesin on growth of gastrinoma (PT) in vivo.

Authors:  K U Chu; J Ishizuka; J F Battey; T Uchida; R D Beauchamp; C M Townsend; J C Thompson
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

3.  The Zollinger-Ellison syndrome. A collective surgical experience.

Authors:  D R Farley; J A van Heerden; C S Grant; L J Miller; D M Ilstrup
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

4.  Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene.

Authors:  B M Evers; P L Rady; K Sandoval; I Arany; S K Tyring; R L Sanchez; W H Nealon; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.